DE69933468D1 - Adenovirus-vermittelte gentherapie - Google Patents

Adenovirus-vermittelte gentherapie

Info

Publication number
DE69933468D1
DE69933468D1 DE69933468T DE69933468T DE69933468D1 DE 69933468 D1 DE69933468 D1 DE 69933468D1 DE 69933468 T DE69933468 T DE 69933468T DE 69933468 T DE69933468 T DE 69933468T DE 69933468 D1 DE69933468 D1 DE 69933468D1
Authority
DE
Germany
Prior art keywords
adenovirus
gene therapy
mediated gene
useful
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69933468T
Other languages
English (en)
Other versions
DE69933468T2 (de
DE69933468T3 (de
Inventor
A I Yla-Herttuala
Anu-Maaria Sandmair
Sami Loimas
Matti Vapalahti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ark Therapeutics Ltd
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69933468(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Application granted granted Critical
Publication of DE69933468D1 publication Critical patent/DE69933468D1/de
Publication of DE69933468T2 publication Critical patent/DE69933468T2/de
Publication of DE69933468T3 publication Critical patent/DE69933468T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE69933468T 1998-11-06 1999-11-05 Adenovirus-vermittelte gentherapie Expired - Lifetime DE69933468T3 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9824437 1998-11-06
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy
EP99971860A EP1135513B2 (de) 1998-11-06 1999-11-05 Adenovirus-vermittelte gentherapie
PCT/EP1999/009017 WO2000028059A1 (en) 1998-11-06 1999-11-05 Adenovirus-mediated gene therapy

Publications (3)

Publication Number Publication Date
DE69933468D1 true DE69933468D1 (de) 2006-11-16
DE69933468T2 DE69933468T2 (de) 2007-01-11
DE69933468T3 DE69933468T3 (de) 2012-01-19

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69933468T Expired - Lifetime DE69933468T3 (de) 1998-11-06 1999-11-05 Adenovirus-vermittelte gentherapie

Country Status (18)

Country Link
US (1) US6579855B1 (de)
EP (1) EP1135513B2 (de)
JP (1) JP4733833B2 (de)
KR (1) KR20020013473A (de)
CN (1) CN1184321C (de)
AT (1) ATE341639T1 (de)
AU (1) AU749451B2 (de)
CA (1) CA2348624C (de)
CY (1) CY1106198T1 (de)
DE (1) DE69933468T3 (de)
DK (1) DK1135513T4 (de)
ES (1) ES2273521T5 (de)
GB (1) GB9824437D0 (de)
HU (1) HUP0104046A3 (de)
NO (1) NO330776B1 (de)
PL (1) PL193076B1 (de)
PT (1) PT1135513E (de)
WO (1) WO2000028059A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
BR112014019431A8 (pt) 2012-02-07 2017-07-11 Global Bio Therapeutics Usa Inc Método compartimentalizado de distribuição de ácido nucleico e composições e usos desses
EP2994168A4 (de) * 2013-05-08 2016-10-05 Finvector Vision Therapies Ltd Behandlung von operablem hochgradigem gliom mit sitimagen-ceradenovec-gentherapie und ganciclovir
DK3030163T3 (da) 2013-08-08 2019-07-01 Global Bio Therapeutics Inc Klemmeindretning til minimalt invasive procedurer
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
MX2022007754A (es) 2019-12-20 2022-07-19 Regeneron Pharma Nuevos agonistas de il2 y metodos de uso de estos.
EP4149963A1 (de) 2020-05-12 2023-03-22 Regeneron Pharmaceuticals, Inc. Neue il10-agonisten und verfahren zur verwendung davon
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
TW202321282A (zh) 2021-07-19 2023-06-01 美商再生元醫藥公司 Il12受體促效劑及其使用方法
TW202334223A (zh) 2021-11-11 2023-09-01 美商再生元醫藥公司 Ｃｄ２０－ｐｄ１結合分子及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) * 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
DE69933468T2 (de) 2007-01-11
PL349489A1 (en) 2002-07-29
CN1184321C (zh) 2005-01-12
DK1135513T3 (da) 2006-11-27
CA2348624A1 (en) 2000-05-18
HUP0104046A2 (hu) 2002-01-28
ES2273521T3 (es) 2007-05-01
ATE341639T1 (de) 2006-10-15
GB9824437D0 (en) 1999-01-06
DE69933468T3 (de) 2012-01-19
HUP0104046A3 (en) 2003-09-29
CN1325450A (zh) 2001-12-05
ES2273521T5 (es) 2011-12-28
DK1135513T4 (da) 2011-11-21
US6579855B1 (en) 2003-06-17
AU1385100A (en) 2000-05-29
PT1135513E (pt) 2006-12-29
EP1135513A1 (de) 2001-09-26
CA2348624C (en) 2012-07-31
NO330776B1 (no) 2011-07-11
EP1135513B1 (de) 2006-10-04
EP1135513B2 (de) 2011-08-10
CY1106198T1 (el) 2011-06-08
KR20020013473A (ko) 2002-02-20
NO20012220L (no) 2001-05-04
JP4733833B2 (ja) 2011-07-27
WO2000028059A1 (en) 2000-05-18
AU749451B2 (en) 2002-06-27
PL193076B1 (pl) 2007-01-31
JP2002529097A (ja) 2002-09-10
NO20012220D0 (no) 2001-05-04

Similar Documents

Publication Publication Date Title
CY1106198T1 (el) Γονιδιακη θepαπεια που διαμεσολαβειται απο αδενοϊο
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
AU1939200A (en) Electrochemical treatment of malignant tumors
JO2248B1 (en) Pirazolobenzodiazepines
AU3891299A (en) Combination therapy for treatment of depression
NO20005885D0 (no) Kombinasjonsterapi for behandling av refraktær depresjon
AU3552399A (en) Recombinant poliovirus for the treatment of cancer
AU1264200A (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
DE59510240D1 (de) Hochfrequenztherapieeinrichtung zur interstitiellen Thermotherapie von Tumoren
FI962114A (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
DK1083934T3 (da) Genterapifremgangsmåder
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
DE69738803D1 (de) Apoptosis induzierendes protein und dieses kodierendes gen
ZA200110436B (en) Therapeutic use of melatonin.
HUP0101947A3 (en) Combination for the treatment of tumors
MXPA02001204A (es) Compuestos calciliticos.
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi
IS5324A (is) (S) 2-Metýlamínó-2-fenýl-n-bútýl 3,4,5-trímetoxý-bensóat, notkun þess til meðferðar á langvinnum sársauka
PT1064014E (pt) Medicamento para o impedimento ou tratamento de tumores especificos de papilomavirus
AU5778399A (en) Gene therapy for treatment of cancer
AU2199901A (en) The treatment of convulsive states
HU9700425D0 (en) Use of incubated, citrate-containing leukaemic blood-product for treating tumors
ZA992063B (en) Suicide gene therapy system for the treatment of brain tumours.
DE29722856U1 (de) Wirbelsäulen-Therapieliege

Legal Events

Date Code Title Description
8363 Opposition against the patent
R102 Epo decision maintaining patent in amended form now final

Ref document number: 1135513

Country of ref document: EP

Effective date: 20110810